The CYP3A4∗22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients

Pharmacogenomics Journal

Volumn 15, Issue 2, 2015, Pages 144-152

  De Jonge, H ^a   Elens, L ^b,c   De Loor, H ^a   Van Schaik, R H ^b   Kuypers, D R J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOSINE; METHYLPREDNISOLONE; MIDAZOLAM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMINE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYP3A4 GENE; CYP3A5 GENE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE TITRATION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE; GENOTYPE; GRAFT RECIPIENT; HUMAN; IN VIVO STUDY; KIDNEY ALLOGRAFT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; ALLELE; GENETICS; KIDNEY TRANSPLANTATION; MIDDLE AGED;

ALLELES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDAZOLAM; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 84925633917     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2014.49     Document Type: Article

References (34)

1. de Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009; 31: 416-435.
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-653.
3. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836-847.
4. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374-1381.
5. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-6080.
6. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-1294.
7. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-172.
8. de Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando) 2008; 22: 6-20.
9. Hesselink DA, Bouamar R, Elens L, van Schaik RH, van GT. The role of pharma-cogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 2013; 53: 123-139.
10. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
11. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
12. Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, Schladt D et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300-308.
13. Elens L, van Schaik RH, Panin N, De MM, Wallemacq P, Lison D et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmaco-genomics 2011; 12: 1383-1396.
14. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van GT et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574-1583.
15. Tavira B, Coto E, Diaz-Corte C, Alvarez V, Lopez-Larrea C, Ortega F. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients. Pharmacogenet Genomics 2013; 23: 445-448.
16. Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol 2014; 70: 685-693.
17. Moes DJ, Swen JJ, den HJ, van der Straaten T, van der Heide JJ, Sanders JS et al. Effect of CYP3A4∗22, CYP3A5∗3, and CYP3A combined genotypes on cyclo-sporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometrics Syst Pharmacol 2014; 3: e100.
18. Santoro AB, Struchiner CJ, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Suarez-Kurtz G. CYP3A5 genotype, but not CYP3A4∗1b, CYP3A4∗22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin Pharmacol Ther 2013; 94: 201-202.
19. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmaco-genomics J 2011; 11: 274-286.
20. Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. CYP3A4 intron 6 C4T polymorphism (CYP3A4∗22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 2013; 38: 349-354.
21. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V et al. CYP3A4 intron 6 C4T SNP (CYP3A4∗22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmaco-genomics 2013; 14: 37-49.
22. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. Pharmaco-genomics 2013; 14: 1467-1480.
23. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 2012; 92: 366-375.
24. de Jonge H, e Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Clin Pharmacol Ther 2011; 90: 414-422.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
26. de Loor H, de Jonge H, Verbeke K, Vanrenterghem Y, Kuypers DR. A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxy-midazolam in human plasma. Biomed Chromatogr 2011; 25: 1091-1098.
27. Napoli KL, Hammett-Stabler C, Taylor PJ, Lowe W, Franklin ME, Morris MR et al. Multi-center evaluation of a commercial Kit for tacrolimus determination by LC/MS/MS. Clin Biochem 2010; 43: 910-920.
28. Gaunt TR, Rodriguez S, Day IN. Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 2007; 8: 428.
29. Elens L, Capron A, van Schaik RH, De MM, De PL, Eddour DC et al. Impact of CYP3A4∗22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit 2013; 35: 608-616.
30. Asberg A, Midtvedt K, van GM, Storset E, Bremer S, Bergan S et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int 2013; 26: 1198-1207.
31. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409-2414.
32. Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 2002; 74: 1419-1424.
33. van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16: 721-725.
34. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711-725.